Skip to main content
. 2011 May 31;16(6):820–834. doi: 10.1634/theoncologist.2010-0259

Table 3.

Clinical pharmacogenetics of cytidine deaminase (CDA) and bleomycin hydrolase (BLMH)

graphic file with name onc00611-0812-t03.jpg

aAdapted from http://www.cancer.gov. See also Table 1.

Abbreviations: HOM, homozygous mutant patients; NA, not analyzed; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; SNP, single nucleotide polymorphism; TTP, time to progression; WT, wild-type patients.